Cargando…

The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPARγ-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells

Thiazolidinediones (TZDs) dramatically reduce the growth of human prostate cancer cells in vitro and in vivo. To determine whether the antitumor effects of TZDs were due in part to changes in the MEK/Erk signaling pathway, we examined the regulation of Erk phosphorylation by the TZD troglitazone wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bolden, Adrienne, Bernard, Lynikka, Jones, Danielle, Akinyeke, Tunde, Stewart, LaMonica V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289875/ https://www.ncbi.nlm.nih.gov/pubmed/22448169 http://dx.doi.org/10.1155/2012/929052

Ejemplares similares

The Androgen Receptor Regulates PPARγ Expression and Activity in Human Prostate Cancer Cells
por: Olokpa, Emuejevoke, et al.
Publicado: (2016)

Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells
por: Rashid-Kolvear, Fariborz, et al.
Publicado: (2010)

PPARγ and MEK Interactions in Cancer
por: Burgermeister, Elke, et al.
Publicado: (2008)

Serum regulates adipogenesis of mesenchymal stem cells via MEK/ERK-dependent PPARγ expression and phosphorylation
por: Wu, Ling, et al.
Publicado: (2010)

Troglitazone Attenuates TGF-β1-Induced EMT in Alveolar Epithelial Cells via a PPARγ-Independent Mechanism
por: Zhou, Beiyun, et al.
Publicado: (2012)

Troglitazone suppresses tumor cell growth and glutamine metabolism through a PPAR-independent mechanism
por: Reynolds, Miriam, et al.
Publicado: (2014)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux
por: Nazim, Uddin MD., et al.
Publicado: (2017)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Crosstalk between the Androgen Receptor and PPAR Gamma Signaling Pathways in the Prostate
por: Olokpa, Emuejevoke, et al.
Publicado: (2017)

Phosphorylation of PPARγ Affects the Collective Motions of the PPARγ-RXRα-DNA Complex
por: Lemkul, Justin A., et al.
Publicado: (2015)

Troglitazone, a PPAR-γ activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-α
por: Sasaki, Makoto, et al.
Publicado: (2005)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

Dihydromyricetin enhances glucose uptake by inhibition of MEK/ERK pathway and consequent down‐regulation of phosphorylation of PPARγ in 3T3‐L1 cells
por: Liu, Lei, et al.
Publicado: (2017)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
por: Kulkarni, Ajit A., et al.
Publicado: (2012)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

The antidiabetic drug troglitazone protects against PrP (106–126)-induced neurotoxicity via the PPARγ-autophagy pathway in neuronal cells
por: Moon, Ji-Hong, et al.
Publicado: (2021)

Obesity-linked phosphorylation of PPARγ by cdk5 is a direct target of the anti-diabetic PPARγ ligands
por: Choi, Jang Hyun, et al.
Publicado: (2010)

Nuclear MEK1 Sequesters PPARγ and Bisects MEK1/ERK Signaling: A Non-Canonical Pathway of Retinoic Acid Inhibition of Adipocyte Differentiation
por: Dave, Sandeep, et al.
Publicado: (2014)

Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?
por: Scatena, Roberto, et al.
Publicado: (2008)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

Dual PPAR α/γ Agonists: Continuing Cardiac Concerns
por: Balachandran, Karthik
Publicado: (2019)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Effects of PPARs Agonists on Cardiac Metabolism in Littermate and Cardiomyocyte-Specific PPAR-γ –Knockout (CM-PGKO) Mice
por: Barbieri, Michelangela, et al.
Publicado: (2012)

Screening of saponins and sapogenins from Medicago species as potential PPARγ agonists and X-ray structure of the complex PPARγ/caulophyllogenin
por: Montanari, Roberta, et al.
Publicado: (2016)

PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists
por: Silswal, Neerupma, et al.
Publicado: (2012)

An Erk/Cdk5 axis controls the diabetogenic actions of PPARγ
por: Banks, Alexander S., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r057kip4dbgvfpfhsbbnhb0018